EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

Stavroula Smilkou iD, Aliki Ntzifa iD, Victoria Tserpeli, Ioanna Balgkouranidou, Alkistis Papatheodoridi, Evangelia Razis, Helena Linardou, Christos Papadimitriou, Amanda Psyrri, Flora Zagouri, Stylianos Kakolyris, Evi Lianidou iD

Molecular Oncology · 2025-07 · 19 (7) · 2109-2119

DOI: 10.1002/1878-0261.13787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 04.01.2025. Verfasst von Stavroula Smilkou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Greece. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Neoplastic Cells, Circulating, Circulating Tumor DNA, Mutation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research-Create-Innovate.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma cell‐free DNA (cfDNA) analysis to track estrogen receptor 1 ( ESR1 ) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breast cancer (MBC). Plasma‐cfDNA is, up to now, the most frequent liquid biopsy analyte used to evaluate ESR1 mutational status. Circulating tumor cell (CTC) enumeration and molecular characterization analysis provides important clinical information in patients with MBC. In this study, we investigated whether analysis of CTCs and circulating tumor DNA (ctDNA) provide similar or complementary information for the analysis of ESR1 mutations. We analyzed both plasma‐cfDNA ( n = 90) and paired CTC‐derived genomic DNA (gDNA; n = 42) from 90 MBC patients for seven ESR1 mutations. Eight out of 90 (8.9%) plasma‐cfDNA samples tested using the ddPLEX Mutation Detection Assay (Bio‐Rad, Hercules, CA, USA), were found positive for one ESR1 mutation, whereas 11/42 (26.2%) CTC‐derived gDNA samples were found positive for at least one ESR1 mutation. Direct comparison of paired samples ( n = 42) revealed that the ESR1 mutation rate was higher in CTC‐derived gDNA (11/42, 26.2%) than in plasma‐cfDNA (6/42, 14.3%) samples. Our results, using this highly sensitive ddPLEX assay, reveal a higher percentage of mutations in CTC‐derived gDNAs than in paired ctDNA in patients with MBC. CTC‐derived gDNA analysis should be further evaluated as an important and complementary tool to ctDNA for identifying patients with ESR1 mutations and for guiding individualized therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor alphaNeoplastic Cells, CirculatingCirculating Tumor DNAMutationBreast NeoplasmsPolymerase Chain ReactionCell-Free Nucleic AcidsHumansFemaleMiddle AgedAgedAdultAged, 80 and over

Stichwörter der Autor:innen

ESR1 mutationsbreast cancercirculating tumor DNAcirculating tumor cellsdroplet digital PCRliquid biopsyplasma cell‐free DNA

Substanzen

Estrogen Receptor alphaESR1 protein, humanCirculating Tumor DNACell-Free Nucleic Acids

Autor:innen und Institutionen

  • Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Greece.
  • Department of Medical Oncology, University General Hospital of Alexandroupolis, Greece.
  • Department of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Hygeia Hospital, Athens, Greece.
  • Oncology Unit, Metropolitan Hospital, Athens, Greece.
  • Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens, Greece.

ORCID-Profile: Stavroula Smilkou, Aliki Ntzifa, Evi Lianidou

Förderung

  • Research-Create-Innovate

Zitieren

APA

Smilkou, S., Ntzifa, A., Tserpeli, V., Balgkouranidou, I., Papatheodoridi, A., Razis, E., Linardou, H., Papadimitriou, C., Psyrri, A., Zagouri, F., Kakolyris, S., & Lianidou, E. (2025). Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR. Molecular Oncology, 19(7), 2109-2119. https://doi.org/10.1002/1878-0261.13787

Vancouver

Smilkou S, Ntzifa A, Tserpeli V, Balgkouranidou I, Papatheodoridi A, Razis E, et al. Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR. Molecular Oncology. 2025;19(7):2109-2119. doi:10.1002/1878-0261.13787

BibTeX
@article{Smilkou2025,
  author = {Smilkou, Stavroula and Ntzifa, Aliki and Tserpeli, Victoria and Balgkouranidou, Ioanna and Papatheodoridi, Alkistis and Razis, Evangelia and Linardou, Helena and Papadimitriou, Christos and Psyrri, Amanda and Zagouri, Flora and Kakolyris, Stylianos and Lianidou, Evi},
  title = {Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR},
  journal = {Molecular Oncology},
  year = {2025},
  volume = {19},
  number = {7},
  pages = {2109--2119},
  doi = {10.1002/1878-0261.13787}
}
Kostenlos starten →